regorafenib + dabrafenib + trametinib

This triplet therapy is an investigational combination regimen being evaluated by the Universitair Ziekenhuis Brussel (UZ Brussel) for the treatment of advanced, pretreated melanoma. The regimen consists of the oral multi-kinase inhibitor regorafenib (Stivarga) administered in combination with a standard-of-care BRAF inhibitor and MEK inhibitor pair, such as dabrafenib plus trametinib or encorafenib plus binimetinib. Regorafenib targets multiple kinases involved in angiogenesis (VEGFR1-3, TIE2), oncogenesis (KIT, RET, RAF-1, BRAF), and the tumor microenvironment (PDGFR, FGFR). By adding regorafenib to the targeted MAPK pathway inhibition provided by BRAF and MEK inhibitors, the therapy aims to overcome acquired resistance and improve outcomes in patients who have progressed on prior immune checkpoint inhibitors and standard targeted therapies, including those with refractory melanoma brain metastases.

Brand names

StivargaTafinlarMekinistBraftoviMektovi

Other names

regorafenib + encorafenib + binimetinibtriplet therapy-Universitair Ziekenhuis Brussel-melanoma